Late mortality rates ‘inadvertently reversed’ in 5-year study of paclitaxel-eluting stent

The journal Circulation said this week that the all-cause mortality rates in a study comparing a paclitaxel stent and percutaneous transluminal angioplasty in people with peripheral artery disease were “inadvertently reversed” by the authors.

In the first version of the paper, originally published in 2016, researchers reported that the 5-year all-cause mortality rate for people treated with Cook Medical‘s Zilver PTX stent was 10.2% and 16.9% for the PTA group. But the correction reversed those numbers.

Get the full story at our sister site, Drug Delivery Business News.

The post Late mortality rates ‘inadvertently reversed’ in 5-year study of paclitaxel-eluting stent appeared first on MassDevice.

from MassDevice https://ift.tt/2GDbCqi